Polymyxin B in combination with rifampin and meropenem against polymyxin B-resistant KPC-producing Klebsiella pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 2, 2017, Pages

  Diep, John K ^a   Jacobs, David M ^a   Sharma, Rajnikant ^a   Covelli, Jenna ^a   Bowers, Dana R ^b   Russo, Thomas A ^a   Rao, Gauri G ^a,c  

^a UNIVERSITY AT BUFFALO   (United States)

^b Kingman Regional Medical Center   (United States)

^c UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

Carbapenemase; Klebsiella pneumoniae; Pharmacodynamics; Polymyxin B; Triple combination

Indexed keywords

BACTERIAL ENZYME; CARBAPENEMASE; MEROPENEM; POLYMYXIN B; RIFAMPICIN; ANTIINFECTIVE AGENT; BETA LACTAMASE; THIENAMYCIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; COMPARATIVE EFFECTIVENESS; COMPARTMENT MODEL; CONTROLLED STUDY; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL; STEADY STATE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; POLYMYXIN B; RIFAMPIN; THIENAMYCINS;

EID: 85011066639     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02121-16     Document Type: Article

References (54)

1. Queenan AM, Bush K. 2007. Carbapenemases: the versatile betalactamases. Clin Microbiol Rev 20:440-458. https://doi.org/10.1128/ CMR.00001-07.
2. Bush K. 2010. Alarming beta-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. Curr Opin Microbiol 13: 558-564. https://doi.org/10.1016/j.mib.2010.09.006.
3. Nordmann P, Naas T, Poirel L. 2011. Global spread of carbapenemaseproducing Enterobacteriaceae. Emerg Infect Dis 17:1791-1798. https:// doi.org/10.3201/eid1710.110655.
4. Ho J, Tambyah PA, Paterson DL. 2010. Multiresistant Gram-negative infections: a global perspective. Curr Opin Infect Dis 23:546-553. https:// doi.org/10.1097/QCO.0b013e32833f0d3e.
5. Anonymous. 2013. Antibiotic/antimicrobial resistance: biggest threats. Centers for Disease Control and Prevention, Atlanta, GA. http:// www.cdc.gov/drugresistance/biggest-threats.html. Accessed 2 October 2015.
6. Borer A, Saidel-Odes L, Riesenberg K, Eskira S, Peled N, Nativ R, Schlaeffer F, Sherf M. 2009. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 30: 972-976. https://doi.org/10.1086/605922.
7. Ben-David D, Kordevani R, Keller N, Tal I, Marzel A, Gal-Mor O, Maor Y, Rahav G. 2012. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect 18:54-60. https://doi.org/ 10.1111/j.1469-0691.2011.03478.x.
8. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M. 2012. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 55: 943-950. https://doi.org/10.1093/cid/cis588.
9. Falagas ME, Kasiakou SK. 2005. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 40:1333-1341. https://doi.org/10.1086/429323.
10. Giamarellou H, Poulakou G. 2009. Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs 69:1879-1901. https://doi.org/10.2165/11315690-000000000-00000.
11. Cannatelli A, Di Pilato V, Giani T, Arena F, Ambretti S, Gaibani P, D'Andrea MM, Rossolini GM. 2014. In vivo evolution to colistin resistance by PmrB sensor kinase mutation in KPC-producing Klebsiella pneumoniae is associated with low-dosage colistin treatment. Antimicrob Agents Chemother 58:4399-4403. https://doi.org/10.1128/AAC.02555-14.
12. Meletis G, Tzampaz E, Sianou E, Tzavaras I, Sofianou D. 2011. Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother 66:946-947. https://doi.org/10.1093/jac/dkr007.
13. Kontopoulou K, Protonotariou E, Vasilakos K, Kriti M, Koteli A, Antoniadou E, Sofianou D. 2010. Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 beta-lactamase resistant to colistin. J Hosp Infect 76:70-73. https://doi.org/10.1016/j.jhin.2010.03.021.
14. Toth A, Damjanova I, Puskas E, Janvari L, Farkas M, Dobak A, Borocz K, Paszti J. 2010. Emergence of a colistin-resistant KPC-2-producing Klebsiella pneumoniae ST258 clone in Hungary. Eur J Clin Microbiol Infect Dis 29:765-769. https://doi.org/10.1007/s10096-010-0921-3.
15. Monaco M, Giani T, Raffone M, Arena F, Garcia-Fernandez A, Pollini S, Grundmann H, Pantosti A, Rossolini GM. 2014. Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, November 2013 to April 2014. Euro Surveill 19(42):pii-20939. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId-20939.
16. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH, Shen J. 2016. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 16:161-168. https://doi.org/10.1016/S1473-3099(15)00424-7.
17. Capone A, Giannella M, Fortini D, Giordano A, Meledandri M, Ballardini M, Venditti M, Bordi E, Capozzi D, Balice MP, Tarasi A, Parisi G, Lappa A, Carattoli A, Petrosillo N. 2013. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect 19:E23-E30. https://doi.org/10.1111/1469-0691.12070.
18. Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, Losito AR, Bartoletti M, Del Bono V, Corcione S, Maiuro G, Tedeschi S, Celani L, Cardellino CS, Spanu T, Marchese A, Ambretti S, Cauda R, Viscoli C, Viale P, ISGRI-SITA. 2015. Infections caused by KPCproducing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 70:2133-2143. https:// doi.org/10.1093/jac/dkv086.
19. Zarkotou O, Pournaras S, Voulgari E, Chrysos G, Prekates A, Voutsinas D, Themeli-Digalaki K, Tsakris A. 2010. Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case-control study. J Clin Microbiol 48: 2271-2274. https://doi.org/10.1128/JCM.02301-09.
20. Tascini C, Tagliaferri E, Giani T, Leonildi A, Flammini S, Casini B, Lewis R, Ferranti S, Rossolini GM, Menichetti F. 2013. Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 57:3990-3993. https:// doi.org/10.1128/AAC.00179-13.
21. Pankey GA, Ashcraft DS. 2011. Detection of synergy using the combination of polymyxin B with either meropenem or rifampin against carbapenemase-producing Klebsiella pneumoniae. Diagn Microbiol Infect Dis 70:561-564. https://doi.org/10.1016/j.diagmicrobio.2011.05.003.
22. Gaibani P, Lombardo D, Lewis RE, Mercuri M, Bonora S, Landini MP, Ambretti S. 2014. In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPCproducing Klebsiella pneumoniae bloodstream isolates. J Antimicrob Chemother 69:1856-1865. https://doi.org/10.1093/jac/dku065.
23. Elemam A, Rahimian J, Doymaz M. 2010. In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae. J Clin Microbiol 48:3558-3562. https://doi.org/10.1128/ JCM.01106-10.
24. Bratu S, Tolaney P, Karumudi U, Quale J, Mooty M, Nichani S, Landman D. 2005. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 56:128-132. https://doi.org/ 10.1093/jac/dki175.
25. Boucher HW, Talbot GH, Benjamin DK, Jr, Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA, Gilbert D, Infectious Diseases Society of America. 2013. 10 '20 progress - development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 56:1685-1694. https://doi.org/10.1093/cid/ cit152.
26. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y. 2012. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 56: 2108-2113. https://doi.org/10.1128/AAC.06268-11.
27. Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, Prekates A, Themeli-Digalaki K, Tsakris A. 2011. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 17:1798-1803. https://doi.org/10.1111/j.1469-0691.2011.03514.x.
28. Barth N, Ribeiro VB, Zavascki AP. 2015. In vitro activity of polymyxin B plus imipenem, meropenem, or tigecycline against KPC-2-producing Enterobacteriaceae with high MICs for these antimicrobials. Antimicrob Agents Chemother 59:3596-3597. https://doi.org/ 10.1128/AAC.00365-15.
29. Toledo PV, Aranha AA, Jr, Arend LN, Ribeiro V, Zavascki AP, Tuon FF. 2015. Activity of antimicrobial combinations against KPC-2-producing Klebsiella pneumoniae in a rat model and time-kill assay. Antimicrob Agents Chemother 59:4301-4304. https://doi.org/ 10.1128/AAC.00323-15.
30. Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, Stefanou I, Sypsa V, Miriagou V, Nepka M, Georgiadou S, Markogiannakis A, Goukos D, Skoutelis A. 2014. Carbapenemaseproducing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 58:2322-2328. https://doi.org/ 10.1128/AAC.02166-13.
31. Tangden T, Hickman RA, Forsberg P, Lagerback P, Giske CG, Cars O. 2014. Evaluation of double-and triple-antibiotic combinations for VIM-and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments. Antimicrob Agents Chemother 58:1757-1762. https://doi.org/10.1128/ AAC.00741-13.
32. Urban C, Mariano N, Rahal JJ. 2010. In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrugresistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob Agents Chemother 54: 2732-2734. https://doi.org/10.1128/AAC.01768-09.
33. Biancofiore G, Tascini C, Bisa M, Gemignani G, Bindi ML, Leonildi A, Giannotti G, Menichetti F. 2007. Colistin, meropenem and rifampin in a combination therapy for multi-drug-resistant Acinetobacter baumannii multifocal infection. A case report. Minerva Anestesiol 73:181-185.
34. Velkov T, Thompson PE, Nation RL, Li J. 2010. Structure-activity relationships of polymyxin antibiotics. J Med Chem 53:1898-1916. https:// doi.org/10.1021/jm900999h.
35. Rao GG, Ly NS, Haas CE, Garonzik S, Forrest A, Bulitta JB, Kelchlin PA, Holden PN, Nation RL, Li J, Tsuji BT. 2014. New dosing strategies for an old antibiotic: pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver disease. Antimicrob Agents Chemother 58:1381-1388. https://doi.org/10.1128/ AAC.00327-13.
36. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, Lephart P, Kaye KS. 2011. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 53:879-884. https://doi.org/10.1093/cid/cir611.
37. Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zavascki AP. 2014. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 43: 349-352. https://doi.org/10.1016/j.ijantimicag.2013.12.002.
38. Monteiro J, Widen RH, Pignatari AC, Kubasek C, Silbert S. 2012. Rapid detection of carbapenemase genes by multiplex real-time PCR. J Antimicrob Chemother 67:906-909. https://doi.org/10.1093/jac/dkr563.
39. Poirel L, Jayol A, Bontron S, Villegas MV, Ozdamar M, Turkoglu S, Nordmann P. 2015. The mgrB gene as a key target for acquired resistance to colistin in Klebsiella pneumoniae. J Antimicrob Chemother 70:75-80. https://doi.org/10.1093/jac/dku323.
40. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Bordinhao RC, Wang J, Forrest A, Nation RL, Li J, Zavascki AP. 2013. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 57:524-531. https://doi.org/10.1093/cid/cit334.
41. Zavascki AP, Goldani LZ, Cao G, Superti SV, Lutz L, Barth AL, Ramos F, Boniatti MM, Nation RL, Li J. 2008. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 47:1298-1304. https:// doi.org/10.1086/592577.
42. Ruslami R, Nijland HM, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse RE. 2007. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother 51:2546-2551. https://doi.org/ 10.1128/AAC.01550-06.
43. Loos U, Musch E, Jensen JC, Mikus G, Schwabe HK, Eichelbaum M. 1985. Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin Wochenschr 63:1205-1211. https://doi.org/10.1007/ BF01733779.
44. Jaruratanasirikul S, Sriwiriyajan S, Punyo J. 2005. Comparison of the pharmacodynamics of meropenem in patients with ventilatorassociated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother 49:1337-1339. https:// doi.org/10.1128/AAC.49.4.1337-1339.2005.
45. Conte JE, Jr, Golden JA, Kelley MG, Zurlinden E. 2005. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem. Int J Antimicrob Agents 26:449-456. https://doi.org/10.1016/j.ijantimicag.2005.08.015.
46. AstraZeneca. 2013. MerremIV package insert. AstraZeneca Pharmaceuticals LP, Wilmington, DE.
47. Chimata M, Nagase M, Suzuki Y, Shimomura M, Kakuta S. 1993. Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease. Antimicrob Agents Chemother 37:229-233. https://doi.org/10.1128/AAC.37.2.229.
48. Lee HJ, Bergen PJ, Bulitta JB, Tsuji B, Forrest A, Nation RL, Li J. 2013. Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 57:3738-3745. https://doi.org/10.1128/AAC.00703-13.
49. Cheah SE, Bulitta JB, Li J, Nation RL. 2014. Development and validation of a liquid chromatography-mass spectrometry assay for polymyxin B in bacterial growth media. J Pharm Biomed Anal 92:177-182. https:// doi.org/10.1016/j.jpba.2014.01.015.
50. Siddhartha TS, Prasanthi B, Santosh T, Ratna JV. 2012. Development and validation of high performance liquid chromatographic method for the determination of rifampicin in human plasma. Int J Pharm Pharm Sci 4:362-367.
51. Kameda K, Ikawa K, Ikeda K, Morikawa N, Nakashima A, Ohge H, Sueda T. 2010. HPLC method for measuring meropenem and biapenem concentrations in human peritoneal fluid and bile: application to comparative pharmacokinetic investigations. J Chromatogr Sci 48:406-411. https://doi.org/10.1093/chromsci/48.5.406.
52. Rao GG, Jacobs DM, Bowers DR, Bulitta JB, Forrest A, Holden P, Nation RL, Li J, Russo TA, Tsuji BT. Pharmacodynamics of polymyxin B combinations against Klebsiella pneumoniae carbapenemase (KPC) producing Klebsiella pneumoniae, abstr A-036. Abstr 54th Intersci Conf Antimicrob Agents Chemother, Washington, DC, 5 to 9 September 2014.
53. Diep JK, Sharma R, Covelli J, Jacobs DM, Bowers DR, Forrest A, Russo TA, Rao GG. Novel triple antibiotic combinations for polymyxin B (PB) resistant Klebsiella pneumoniae (KP) expressing KPC, abstr A-945. Abstr 55th Intersci Conf Antimicrob Agents Chemother, San Diego, CA, 17 to 21 September 2015.
54. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.